8-Hydroxy-2′-deoxyguanosine as a biomarker of oxidative stress in acute exacerbation of chronic obstructive pulmonary disease
8-Hydroxy-2′-deoxyguanosine as a biomarker of oxidative stress in acute exacerbation of chronic obstructive pulmonary disease
复制标题
8-羟基-2-脱氧鸟苷作为慢性阻塞性肺疾病急性加重中氧化应激的生物标志物
DOI：
10.3906/sag-1807-106
复制
发表时间：
2019-01-01
影响因子：
2.3
通讯作者：
Feng, Ganzhu
中科院分区：
文献类型：
--
作者：
Liu, Xing;Deng, Kaili;Feng, Ganzhu
背景/目的：8-羟基-2 '-脱氧鸟苷（8-OHdG）是氧化应激的生物标志物，与许多疾病有关。为探讨慢性阻塞性肺疾病急性加重期（AECOPD）患者血浆8-羟脱氧葡萄糖（8-OHdG）水平的临床意义，材料与方法：共纳入154例受试者，其中健康志愿者20例，COPD稳定期患者24例，AECOPD患者110例。在招募入组研究时，采集所有受试者的外周血样本、人口统计学信息和临床特征。结果：AECOPD患者血浆8-OHdG水平明显高于健康对照组和稳定期COPD患者，尤其是吸烟者。它还随着GOLD分期、mMRC等级、CAT评分和组合COPT评估的组水平而增加。进一步分析显示，8-OHdG与FEV 1、FEV1%预计值、FEV 1/FVC呈负相关，与C反应蛋白、降钙素原、中性粒细胞CD 64呈正相关。8-OHdG与AECOPD患者的肺功能测定严重程度、症状严重程度、加重风险和炎症生物标志物相关，提示其作为反映疾病严重程度和指导最佳治疗决策选择的有前景的生物标志物。
Background/aim: 8-Hydroxy-2'-deoxyguanosine (8-OHdG) is a biomarker of oxidative stress and has been implicated in many diseases. The aim of this study was to investigate the clinical value of plasma 8-OHdG level in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD).Materials and methods: A total of 154 subjects were enrolled in this study, including 20 healthy volunteers, 24 COPD patients in the stable phase, and 110 AECOPD patients. Peripheral blood samples, demographic information, and clinical characteristics were collected from all subjects at the time of being recruited into the study. Plasma 8-OIidG level was detected by enzyme-linked immunosorbent assay.Results: 8-OHdG was increased in patients with AECOPD compared to healthy subjects and patients with stable COPD, especially in smokers. It also increased with the GOLD stage, mMRC grade, CAT score, and group level of combined COPT) assessment. Additionally, further analysis revealed that 8-OHdG was negatively correlated with FEV1, FEV1% predicted, and FEV1/FVC and positively correlated with C-reactive protein, procalcitonin, and neutrophil CD64.Conclusion: 8-OHdG is associated with spirometric severity, symptomatic severity, exacerbation risk, and inflammatory biomarkers in AECOPD patients, suggesting it as a promising biomarker for reflecting disease severity and guiding the choice of optimal therapeutic decision.